数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Albert Bourla -- Chairman, Chief Executive Officer and Director 62 3301.75万美元 31.68 2024-02-22
James C. Smith Director 64 40.59万美元 0.35 2024-02-22
Joseph J. Echevarria Director 67 38.59万美元 未持股 2024-02-22
Dan R. Littman -- Director 71 36.79万美元 未持股 2024-02-22
Susan Desmond Hellmann Director 66 35.59万美元 0.34 2024-02-22
Susan Hockfield Director 73 35.87万美元 未持股 2024-02-22
James Quincey Director 59 37.59万美元 未持股 2024-02-22
Shantanu Narayen Director 60 42.59万美元 未持股 2024-02-22
Scott Gottlieb Director 51 55.36万美元 0.90 2024-02-22
Suzanne Nora Johnson Director 67 40.59万美元 1.00 2024-02-22
Ronald E. Blaylock Director 64 36.59万美元 1.30 2024-02-22
Helen H. Hobbs Director 71 40.59万美元 未持股 2024-02-22

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Albert Bourla -- Chairman, Chief Executive Officer and Director 62 3301.75万美元 31.68 2024-02-22
Lidia Fonseca Chief Digital and Technology Officer, Executive Vice President 54 未披露 未持股 2024-02-22
Payal Sahni Chief People Experience Officer, Executive Vice President 49 未披露 未持股 2024-02-22
Aamir Malik -- Chief U.S. Commercial Officer, Executive Vice President 48 未披露 0.04 2024-02-22
Michael McDermott -- Chief Global Supply Officer, Executive Vice President 58 未披露 未持股 2024-02-22
Chris Boshoff -- Chief Oncology Officer, Executive Vice President 60 未披露 未持股 2024-02-22
Alexandre de Germay -- Chief International Commercial Officer, Executive Vice President 56 未披露 未持股 2024-02-22
Jennifer B. Damico -- Senior Vice President and Controller -- 未披露 未持股 2024-02-22
David M. Denton Chief Financial Officer, Executive Vice President 58 2444.42万美元 1.64 2024-02-22
Mikael Dolsten Chief Scientific Officer, President, Pfizer Research 65 1221.82万美元 17.44 2024-02-22
Douglas M. Lankler General Counsel, Executive Vice President 58 712.94万美元 13.70 2024-02-22
Sally Susman Chief Corporate Affairs Officer, Executive Vice President 62 未披露 未持股 2024-02-22
Rady A. Johnson -- Chief Compliance, Quality and Risk Officer, Executive Vice President 62 未披露 未持股 2024-02-22

董事简历

中英对照 |  中文 |  英文
Albert Bourla

Albert Bourla,2014年1月担任一家肿瘤学和消费者保健公司,疫苗的集团总裁。2010年12月到2013年12月担任既定产品业务部门的董事长和总经理。2009年到2010年11月担任Pfizer动物保健欧洲,非洲,亚洲和太平洋地区的总裁。2005年到2009年担任Pfizer动物保健欧洲,非洲和中东地区的总裁。


Albert Bourla,Chairman of the Board since January 2020 and Chief Executive Officer since January 2019. Chief Operating Officer from January 2018 until December 2018. Group President, Pfizer Innovative Health from June 2016 until December 2017. Group President, Global Innovative Pharma Business (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) from February 2016 until June 2016. President and General Manager of Established Products Business Unit from December 2010 until December 2013. Pfizer Inc. Director since February 2018.
Albert Bourla,2014年1月担任一家肿瘤学和消费者保健公司,疫苗的集团总裁。2010年12月到2013年12月担任既定产品业务部门的董事长和总经理。2009年到2010年11月担任Pfizer动物保健欧洲,非洲,亚洲和太平洋地区的总裁。2005年到2009年担任Pfizer动物保健欧洲,非洲和中东地区的总裁。
Albert Bourla,Chairman of the Board since January 2020 and Chief Executive Officer since January 2019. Chief Operating Officer from January 2018 until December 2018. Group President, Pfizer Innovative Health from June 2016 until December 2017. Group President, Global Innovative Pharma Business (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) from February 2016 until June 2016. President and General Manager of Established Products Business Unit from December 2010 until December 2013. Pfizer Inc. Director since February 2018.
James C. Smith

James C. Smith,2012年1月以来,他担任Thomson Reuters Corporation(为企业和专业人士提供智能信息的供应商)的总裁和首席执行官以及董事。从2011年9月到2011年12月,他担任其首席运营官。从2008年到2011年,他担任Thomson Reuters Professional部门首席执行官。2008年Reuters Group PLC被The Thomson Corporation (Thomson)收购之前,他担任Thomson的首席运营官和Thomson Learning的学术和参照部门的总裁兼首席执行官。


James C. Smith,Chairman of the Thomson Reuters Foundation, a London-based charity supported by Thomson Reuters. President and Chief Executive Officer of Thomson Reuters, a provider of intelligent information for businesses and professionals from 2012 through March 2020, its Chief Operating Officer from September 2011 to December 2011, and Chief Executive Officer, Thomson Reuters Professional Division, from 2008 to 2011. Prior to the acquisition of Reuters Group PLC by The Thomson Corporation in 2008, served as Chief Operating Officer of Thomson Corporation and as President and Chief Executive Officer of Thomson Learning's Academic and Reference Group. Director of Refinitiv, a privately-held global provider of financial market data and infrastructure until its acquisition by the London Stock Exchange Group in January 2021. Member of the Board of Governors of Marshall University. Member of the Board of Trustees of the Brookings Institution. Director of Thomson Reuters from 2012 until 2020.
James C. Smith,2012年1月以来,他担任Thomson Reuters Corporation(为企业和专业人士提供智能信息的供应商)的总裁和首席执行官以及董事。从2011年9月到2011年12月,他担任其首席运营官。从2008年到2011年,他担任Thomson Reuters Professional部门首席执行官。2008年Reuters Group PLC被The Thomson Corporation (Thomson)收购之前,他担任Thomson的首席运营官和Thomson Learning的学术和参照部门的总裁兼首席执行官。
James C. Smith,Chairman of the Thomson Reuters Foundation, a London-based charity supported by Thomson Reuters. President and Chief Executive Officer of Thomson Reuters, a provider of intelligent information for businesses and professionals from 2012 through March 2020, its Chief Operating Officer from September 2011 to December 2011, and Chief Executive Officer, Thomson Reuters Professional Division, from 2008 to 2011. Prior to the acquisition of Reuters Group PLC by The Thomson Corporation in 2008, served as Chief Operating Officer of Thomson Corporation and as President and Chief Executive Officer of Thomson Learning's Academic and Reference Group. Director of Refinitiv, a privately-held global provider of financial market data and infrastructure until its acquisition by the London Stock Exchange Group in January 2021. Member of the Board of Governors of Marshall University. Member of the Board of Trustees of the Brookings Institution. Director of Thomson Reuters from 2012 until 2020.
Joseph J. Echevarria

Joseph J. Echevarria,从2011年一直到2014年退休前,在一家全球专业化服务的提供商- Deloitte LLP担任首席执行官。在该公司的36年职业生涯中,曾担任高级职位,不断被提升到重要的位置上,包括被任命为首席执行官之前,担任美国业务一般合伙人。他目前在Miami大学Private Export Council、国际贸易主要国家咨询委员会的理事会任职。还曾被总统奥巴马(Obama)任命为一家旨在想方设法为企业和公民领袖授权男孩和色彩年轻人的联邦机构- My Brother’s Keeper的联席主席。持有Miami大学的工商管理学士学位。


Joseph J. Echevarria,served as CEO of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. Mr. Echevarria previously served in increasingly senior leadership positions during his 36-year career at the firm, including U.S. Managing Partner for Operations, prior to being named CEO.In addition to his current public company board service, Mr. Echevarria serves as a Trustee and CEO of the University of Miami and CEO of the University of Miami Health System. Mr. Echevarria served as a director of Xerox Corporation from 2017 until 2023. Mr. Echevarria previously served as Chairman of President Obama's My Brother's Keeper Alliance and as a Member of the Private Export Council, the principal national advisory committee on international trade. Mr. Echevarria earned his bachelor's degree in business administration from the University of Miami.
Joseph J. Echevarria,从2011年一直到2014年退休前,在一家全球专业化服务的提供商- Deloitte LLP担任首席执行官。在该公司的36年职业生涯中,曾担任高级职位,不断被提升到重要的位置上,包括被任命为首席执行官之前,担任美国业务一般合伙人。他目前在Miami大学Private Export Council、国际贸易主要国家咨询委员会的理事会任职。还曾被总统奥巴马(Obama)任命为一家旨在想方设法为企业和公民领袖授权男孩和色彩年轻人的联邦机构- My Brother’s Keeper的联席主席。持有Miami大学的工商管理学士学位。
Joseph J. Echevarria,served as CEO of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. Mr. Echevarria previously served in increasingly senior leadership positions during his 36-year career at the firm, including U.S. Managing Partner for Operations, prior to being named CEO.In addition to his current public company board service, Mr. Echevarria serves as a Trustee and CEO of the University of Miami and CEO of the University of Miami Health System. Mr. Echevarria served as a director of Xerox Corporation from 2017 until 2023. Mr. Echevarria previously served as Chairman of President Obama's My Brother's Keeper Alliance and as a Member of the Private Export Council, the principal national advisory committee on international trade. Mr. Echevarria earned his bachelor's degree in business administration from the University of Miami.
Dan R. Littman

Dan R. Littman、Helen L。和Martin S.Kimmel自1995年起任纽约大学兰贡医学中心Skirball生物分子医学研究所分子免疫学教授,1987年起任霍华德休斯医学研究所研究员。1985年至1995年,加利福尼亚大学旧金山分校微生物学和免疫学教授。国家科学院和国家医学院院士。美国艺术科学院和美国微生物学院院士。Vedanta Biosciences的创始科学顾问委员会成员,Immunai,Inc.的科学联合创始人和顾问委员会成员。Chemicentryx,Inc.的科学顾问委员会成员,MGH、麻省理工学院和哈佛大学的癌症研究所、博德研究所和拉贡研究所。帕克癌症免疫治疗研究所科学指导委员会成员。荣获2004年纽约市市长科学技术杰出奖、2013年罗斯分子医学奖和2016年维尔切克生物医学奖。


Dan R. Littman,Helen L. and Martin S. Kimmel Professor of Molecular Immunology, Department of Pathology at NYU Grossman School of Medicine. Professor, Department of Microbiology at NYU Grossman School of Medicine since 1995 and Investigator, Howard Hughes Medical Institute, since 1987. Professor of Microbiology and Immunology at the University of California, San Francisco from 1985 to 1995. Member of the National Academy of the Sciences and the National Academy of Medicine. Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology. Founding Scientific Advisory Board Member of Vedanta Biosciences and Scientific co-founder and Advisory Board Member of Immunai, Inc. Member of Scientific Advisory Boards at the Cancer Research Institute, the Broad Institute, IMIDomics, Scleroderma Research Foundation, Whitehead Institute of MIT Board of Advising Scientists and the Ragon Institute of MGH, MIT and Harvard. Member of the Scientific Steering Committee of Parker Institute of Cancer Immunotherapy. Awarded the New York City Mayor's Award for Excellence in Science and Technology (2004), the Ross Prize in Molecular Medicine (2013) and the Vilcek Prize in Biomedical Science (2016).
Dan R. Littman、Helen L。和Martin S.Kimmel自1995年起任纽约大学兰贡医学中心Skirball生物分子医学研究所分子免疫学教授,1987年起任霍华德休斯医学研究所研究员。1985年至1995年,加利福尼亚大学旧金山分校微生物学和免疫学教授。国家科学院和国家医学院院士。美国艺术科学院和美国微生物学院院士。Vedanta Biosciences的创始科学顾问委员会成员,Immunai,Inc.的科学联合创始人和顾问委员会成员。Chemicentryx,Inc.的科学顾问委员会成员,MGH、麻省理工学院和哈佛大学的癌症研究所、博德研究所和拉贡研究所。帕克癌症免疫治疗研究所科学指导委员会成员。荣获2004年纽约市市长科学技术杰出奖、2013年罗斯分子医学奖和2016年维尔切克生物医学奖。
Dan R. Littman,Helen L. and Martin S. Kimmel Professor of Molecular Immunology, Department of Pathology at NYU Grossman School of Medicine. Professor, Department of Microbiology at NYU Grossman School of Medicine since 1995 and Investigator, Howard Hughes Medical Institute, since 1987. Professor of Microbiology and Immunology at the University of California, San Francisco from 1985 to 1995. Member of the National Academy of the Sciences and the National Academy of Medicine. Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology. Founding Scientific Advisory Board Member of Vedanta Biosciences and Scientific co-founder and Advisory Board Member of Immunai, Inc. Member of Scientific Advisory Boards at the Cancer Research Institute, the Broad Institute, IMIDomics, Scleroderma Research Foundation, Whitehead Institute of MIT Board of Advising Scientists and the Ragon Institute of MGH, MIT and Harvard. Member of the Scientific Steering Committee of Parker Institute of Cancer Immunotherapy. Awarded the New York City Mayor's Award for Excellence in Science and Technology (2004), the Ross Prize in Molecular Medicine (2013) and the Vilcek Prize in Biomedical Science (2016).
Susan Desmond Hellmann

Susan Desmond Hellmann是Bill & Melinda Gates基金会的首席执行官,Bill & Melinda Gates基金会致力于加强全球医疗保健,减少极端贫困和扩大教育机会,从2014年到2020年退休,目前继续担任盖茨医学研究所的高级顾问和董事会成员。在加入Bill & Melinda Gates 基金会之前,她曾在2009年至2014年担任加州大学旧金山分校的第一位女校长和第九位总校长。Hellmann博士仍然是加州大学旧金山分校的兼职教授。1995年至2009年,Desmond Hellmann博士受雇于Genentech,2005年至2009年担任产品开发总裁,负责临床前和临床开发、业务开发和产品组合管理。在加入Genentech之前,她是百时美施贵宝制药研究所临床癌症研究副主任。2013年至2019年担任Facebook公司董事。2010年至2017年担任宝洁董事。


Susan Desmond Hellmann,Board Member of National Resilience, Inc. and Stand Up To Cancer. Senior Advisor at GMRI from 2020 until 2021. Served as the Chief Executive Officer of the Bill & Melinda Gates Foundation, a private foundation committed to enhancing global healthcare, reducing extreme poverty and expanding educational opportunities, from 2014 until her retirement in 2020. Prior to joining the Bill & Melinda Gates Foundation, she served as the first female, and ninth overall, Chancellor of UCSF from 2009 to 2014. Dr. Desmond-Hellmann remains an Adjunct Professor at UCSF. Member of the President's Council of Advisors on Science and Technology. From 1995 through 2009, Dr. Desmond-Hellmann was employed at Genentech where she served as President of Product Development from 2005 to 2009, overseeing pre-clinical and clinical development, business development and product portfolio management. Prior to joining Genentech, she was Associate Director, Clinical Cancer Research at Bristol-Myers Squibb Pharmaceutical Research Institute. Director of Facebook Inc. from 2013 to 2019. Director of Procter & Gamble from 2010 to 2017.
Susan Desmond Hellmann是Bill & Melinda Gates基金会的首席执行官,Bill & Melinda Gates基金会致力于加强全球医疗保健,减少极端贫困和扩大教育机会,从2014年到2020年退休,目前继续担任盖茨医学研究所的高级顾问和董事会成员。在加入Bill & Melinda Gates 基金会之前,她曾在2009年至2014年担任加州大学旧金山分校的第一位女校长和第九位总校长。Hellmann博士仍然是加州大学旧金山分校的兼职教授。1995年至2009年,Desmond Hellmann博士受雇于Genentech,2005年至2009年担任产品开发总裁,负责临床前和临床开发、业务开发和产品组合管理。在加入Genentech之前,她是百时美施贵宝制药研究所临床癌症研究副主任。2013年至2019年担任Facebook公司董事。2010年至2017年担任宝洁董事。
Susan Desmond Hellmann,Board Member of National Resilience, Inc. and Stand Up To Cancer. Senior Advisor at GMRI from 2020 until 2021. Served as the Chief Executive Officer of the Bill & Melinda Gates Foundation, a private foundation committed to enhancing global healthcare, reducing extreme poverty and expanding educational opportunities, from 2014 until her retirement in 2020. Prior to joining the Bill & Melinda Gates Foundation, she served as the first female, and ninth overall, Chancellor of UCSF from 2009 to 2014. Dr. Desmond-Hellmann remains an Adjunct Professor at UCSF. Member of the President's Council of Advisors on Science and Technology. From 1995 through 2009, Dr. Desmond-Hellmann was employed at Genentech where she served as President of Product Development from 2005 to 2009, overseeing pre-clinical and clinical development, business development and product portfolio management. Prior to joining Genentech, she was Associate Director, Clinical Cancer Research at Bristol-Myers Squibb Pharmaceutical Research Institute. Director of Facebook Inc. from 2013 to 2019. Director of Procter & Gamble from 2010 to 2017.
Susan Hockfield

Susan Hockfield,神经科学教授,麻省理工学院名誉院长。2004年至2012年担任麻省理工学院第十六任院长。麻省理工学院科赫癌症综合研究所成员。在加入麻省理工学院之前,她曾任William-Edward Gilbert神经生物学教授,1998年至2002年任耶鲁大学艺术与科学研究生院院长,2003年至2004年任耶鲁大学教务长。曾担任美国国务院的科学特使和国会能源部实验室评估委员会成员。先进制造业伙伴关系创始联合主席。美国艺术科学院和神经科学学会会员。获得美国解剖学家协会查尔斯·朱德森·赫里克奖、耶鲁大学威尔伯·卢修斯交叉奖、罗切斯特大学梅里奥拉奖、成就学院金盘奖、妇女联合会阿米莉亚·埃尔哈特奖、爱迪生成就奖,来自大波士顿商会的终身成就巅峰奖和来自研究的杰弗里·比恩科学建设者奖。她曾于2006年至2018年担任通用电气公司董事,2012年至2016年担任高通公司董事。她是美国艺术与科学学院和科学进步美国联合学院的一员。她是先进制造业合作组织的联合主席。她获得多项荣誉学位,波士顿交响乐团的人,纽约卡内基公司理事和麻省理工学院的公司成员。


Susan Hockfield,Professor of Neuroscience and President Emerita at MIT. Served as MIT's sixteenth president from 2004 to 2012. Member, Koch Institute for Integrative Cancer Research at MIT. Prior to joining MIT, she was the William Edward Gilbert Professor of Neurobiology, Dean of the Graduate School of Arts and Sciences from 1998 to 2002 and Provost from 2003 to 2004 at Yale University. Board Member of Repertoire Immune Medicines, Cajal Neuroscience and Break Through Cancer.Served as Science Envoy with the U.S. Department of State and as a member of a Congressional Commission evaluating the Department of Energy laboratories. Founding co-chair of the Advanced Manufacturing Partnership. Fellow of the American Association for the Advancement of Science. Member of the American Academy of Arts and Sciences and the Society for Neuroscience.Recipient of the Charles L. Branch BrainHealth Award, Charles Judson Herrick Award from the American Association of Anatomists, the Wilbur Lucius Cross Award from Yale University, the Meliora Citation from the University of Rochester, the Golden Plate Award from the Academy of Achievement, the Amelia Earhart Award from the Women's Union, the Edison Achievement Award, the Pinnacle Award for Lifetime Achievement from the Greater Boston Chamber of Commerce and the Geoffrey Beene Builders of Science Award from Research!America. She previously served as a Director of General Electric Company from 2006 until 2018 and of Qualcomm Incorporated from 2012 until 2016.
Susan Hockfield,神经科学教授,麻省理工学院名誉院长。2004年至2012年担任麻省理工学院第十六任院长。麻省理工学院科赫癌症综合研究所成员。在加入麻省理工学院之前,她曾任William-Edward Gilbert神经生物学教授,1998年至2002年任耶鲁大学艺术与科学研究生院院长,2003年至2004年任耶鲁大学教务长。曾担任美国国务院的科学特使和国会能源部实验室评估委员会成员。先进制造业伙伴关系创始联合主席。美国艺术科学院和神经科学学会会员。获得美国解剖学家协会查尔斯·朱德森·赫里克奖、耶鲁大学威尔伯·卢修斯交叉奖、罗切斯特大学梅里奥拉奖、成就学院金盘奖、妇女联合会阿米莉亚·埃尔哈特奖、爱迪生成就奖,来自大波士顿商会的终身成就巅峰奖和来自研究的杰弗里·比恩科学建设者奖。她曾于2006年至2018年担任通用电气公司董事,2012年至2016年担任高通公司董事。她是美国艺术与科学学院和科学进步美国联合学院的一员。她是先进制造业合作组织的联合主席。她获得多项荣誉学位,波士顿交响乐团的人,纽约卡内基公司理事和麻省理工学院的公司成员。
Susan Hockfield,Professor of Neuroscience and President Emerita at MIT. Served as MIT's sixteenth president from 2004 to 2012. Member, Koch Institute for Integrative Cancer Research at MIT. Prior to joining MIT, she was the William Edward Gilbert Professor of Neurobiology, Dean of the Graduate School of Arts and Sciences from 1998 to 2002 and Provost from 2003 to 2004 at Yale University. Board Member of Repertoire Immune Medicines, Cajal Neuroscience and Break Through Cancer.Served as Science Envoy with the U.S. Department of State and as a member of a Congressional Commission evaluating the Department of Energy laboratories. Founding co-chair of the Advanced Manufacturing Partnership. Fellow of the American Association for the Advancement of Science. Member of the American Academy of Arts and Sciences and the Society for Neuroscience.Recipient of the Charles L. Branch BrainHealth Award, Charles Judson Herrick Award from the American Association of Anatomists, the Wilbur Lucius Cross Award from Yale University, the Meliora Citation from the University of Rochester, the Golden Plate Award from the Academy of Achievement, the Amelia Earhart Award from the Women's Union, the Edison Achievement Award, the Pinnacle Award for Lifetime Achievement from the Greater Boston Chamber of Commerce and the Geoffrey Beene Builders of Science Award from Research!America. She previously served as a Director of General Electric Company from 2006 until 2018 and of Qualcomm Incorporated from 2012 until 2016.
James Quincey

James Quincey,The Coca-Cola Company,自2019年4月起担任董事长,自2017年5月起担任首席执行官,2015年8月至2018年12月担任总裁,2015年8月至2017年4月担任首席运营官,2013年1月至2015年8月担任欧洲集团总裁,2008年10月至2013年1月担任西北欧总裁和Nordics业务单元总裁。2005年12月至2008年10月墨西哥部门总裁。2003年12月至2005年12月南拉丁部门总裁。1996年加入公司担任拉丁美洲集团学习战略总监,并继续在拉丁美洲担任一系列职责不断增加的运营角色。美中贸易委员会主任兼促使变化的人。商业圆桌会议成员。


James Quincey,Chairman of the Board of Directors since April 2019 and Chief Executive Officer since May 2017. Elected to the Board of Directors in April 2017. President from August 2015 to December 2018, and Chief Operating Officer from August 2015 to April 2017.
James Quincey,The Coca-Cola Company,自2019年4月起担任董事长,自2017年5月起担任首席执行官,2015年8月至2018年12月担任总裁,2015年8月至2017年4月担任首席运营官,2013年1月至2015年8月担任欧洲集团总裁,2008年10月至2013年1月担任西北欧总裁和Nordics业务单元总裁。2005年12月至2008年10月墨西哥部门总裁。2003年12月至2005年12月南拉丁部门总裁。1996年加入公司担任拉丁美洲集团学习战略总监,并继续在拉丁美洲担任一系列职责不断增加的运营角色。美中贸易委员会主任兼促使变化的人。商业圆桌会议成员。
James Quincey,Chairman of the Board of Directors since April 2019 and Chief Executive Officer since May 2017. Elected to the Board of Directors in April 2017. President from August 2015 to December 2018, and Chief Operating Officer from August 2015 to April 2017.
Shantanu Narayen

Shantanu Narayen,Adobe公司的董事长兼首席执行官,Adobe公司是世界上最大、最多元化的软件公司之一。Adobe总裁至2021年12月。在2007年被任命为首席执行官之前,他曾在Adobe担任多个领导职务,包括总裁兼首席运营官,全球产品部执行副总裁,全球产品开发部高级副总裁。美印战略伙伴关系论坛副主席。一直被《巴伦周刊》评为全球最佳CEO之一,并在2020年被《财富》杂志评为“年度最佳企业家”。


Shantanu Narayen,currently serves as Adobe Inc. Chief Executive Officer and Chair of the Board. He joined Adobe in January 1998 as Vice President and General Manager of Adobe Inc. engineering technology group. In January 1999, he was promoted to Senior Vice President, Worldwide Products, and in March 2001, he was promoted to Executive Vice President, Worldwide Product Marketing and Development. In January 2005, Mr. Narayen was promoted to President and Chief Operating Officer, and effective December 2007, he was appointed Adobe Inc. Chief Executive Officer and joined Adobe Inc. Board. In January 2017, he was named Adobe Inc. Chair of the Board. Mr. Narayen holds a B.S. in Electronics Engineering from Osmania University in India, a M.S. in Computer Science from Bowling Green State University and an M.B.A. from the Haas School of Business, University of California, Berkeley.
Shantanu Narayen,Adobe公司的董事长兼首席执行官,Adobe公司是世界上最大、最多元化的软件公司之一。Adobe总裁至2021年12月。在2007年被任命为首席执行官之前,他曾在Adobe担任多个领导职务,包括总裁兼首席运营官,全球产品部执行副总裁,全球产品开发部高级副总裁。美印战略伙伴关系论坛副主席。一直被《巴伦周刊》评为全球最佳CEO之一,并在2020年被《财富》杂志评为“年度最佳企业家”。
Shantanu Narayen,currently serves as Adobe Inc. Chief Executive Officer and Chair of the Board. He joined Adobe in January 1998 as Vice President and General Manager of Adobe Inc. engineering technology group. In January 1999, he was promoted to Senior Vice President, Worldwide Products, and in March 2001, he was promoted to Executive Vice President, Worldwide Product Marketing and Development. In January 2005, Mr. Narayen was promoted to President and Chief Operating Officer, and effective December 2007, he was appointed Adobe Inc. Chief Executive Officer and joined Adobe Inc. Board. In January 2017, he was named Adobe Inc. Chair of the Board. Mr. Narayen holds a B.S. in Electronics Engineering from Osmania University in India, a M.S. in Computer Science from Bowling Green State University and an M.B.A. from the Haas School of Business, University of California, Berkeley.
Scott Gottlieb

Scott Gottlieb,他自2009年1月起担任New Enterprise Associates,Inc.董事,从2019年起为美国企业研究所的常驻研究员。也是在纽约大学医学院的医学临床助理教授。从2005年到2007年,曾在美国食品和药物管理局“FDA”担任副处长,负责医学和科学事务。在此之前,从2003年到2004年担任FDA局长的医疗技术高级顾问和医疗FDA政策发展的董事。于2004年春离开了美国FDA,去完成新的医疗保险药物报销的工作,作为医疗保险和医疗补助服务中心的高级顾问,支持运用相关新的医疗技术,提高质量和覆盖范围和支付决策机构的政策工作。目前担任Molecular Insight Pharmaceuticals的董事。国家医学院院士,财经新闻网CNBC撰稿人,是Sinai School of Medicine和Connecticut Wesleyan University的毕业生。


Scott Gottlieb,Partner, New Enterprise Associates and senior fellow at AEI, a public policy think tank (since 2019);23rd Commissioner, FDA (2017 – 2019);Various roles in the public and private sectors including serving as Venture Partner at New Enterprise Associates (2007 – 2017);FDA Deputy Commissioner for Medical and Scientific Affairs (2005 – 2007);Senior Advisor for Medical Technology to the FDA Commissioner (2003 – 2004).B.A. in Economics from Wesleyan University.M.D. from Mount Sinai School of Medicine of New York University.
Scott Gottlieb,他自2009年1月起担任New Enterprise Associates,Inc.董事,从2019年起为美国企业研究所的常驻研究员。也是在纽约大学医学院的医学临床助理教授。从2005年到2007年,曾在美国食品和药物管理局“FDA”担任副处长,负责医学和科学事务。在此之前,从2003年到2004年担任FDA局长的医疗技术高级顾问和医疗FDA政策发展的董事。于2004年春离开了美国FDA,去完成新的医疗保险药物报销的工作,作为医疗保险和医疗补助服务中心的高级顾问,支持运用相关新的医疗技术,提高质量和覆盖范围和支付决策机构的政策工作。目前担任Molecular Insight Pharmaceuticals的董事。国家医学院院士,财经新闻网CNBC撰稿人,是Sinai School of Medicine和Connecticut Wesleyan University的毕业生。
Scott Gottlieb,Partner, New Enterprise Associates and senior fellow at AEI, a public policy think tank (since 2019);23rd Commissioner, FDA (2017 – 2019);Various roles in the public and private sectors including serving as Venture Partner at New Enterprise Associates (2007 – 2017);FDA Deputy Commissioner for Medical and Scientific Affairs (2005 – 2007);Senior Advisor for Medical Technology to the FDA Commissioner (2003 – 2004).B.A. in Economics from Wesleyan University.M.D. from Mount Sinai School of Medicine of New York University.
Suzanne Nora Johnson

Suzanne Nora Johnson, 是高盛集团有限公司的前副主席,从2004年任职到2007年。她在高盛的21年里,她还担任过全球市场研究所的主席,全球投资研究部主管和全球投资银行医疗保健业务负责人。她目前是Intuit公司收购委员会的主席,并担任审计与风险管理委员会,辉瑞公司审计的董事和薪酬与科学技术委员会成员和Visa公司的薪酬委员会成员,并为提名委员会及企业管治委员会主席。


Suzanne Nora Johnson,Retired Vice Chairman, Goldman Sachs, since 2007. During her 21-year tenure with Goldman Sachs, she served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Health Care.Board Chair of Intuit Inc. Co-Chair, Board of Trustees of The Brookings Institution; Member of the Board of Trustees of the Carnegie Institution of Washington and Chair of the Board of Trustees of the University of Southern California. Member of the American Academy of Arts and Sciences. Director of American International Group, Inc. from 2008 to 2020 and Visa, Inc. from 2007 to 2022.
Suzanne Nora Johnson, 是高盛集团有限公司的前副主席,从2004年任职到2007年。她在高盛的21年里,她还担任过全球市场研究所的主席,全球投资研究部主管和全球投资银行医疗保健业务负责人。她目前是Intuit公司收购委员会的主席,并担任审计与风险管理委员会,辉瑞公司审计的董事和薪酬与科学技术委员会成员和Visa公司的薪酬委员会成员,并为提名委员会及企业管治委员会主席。
Suzanne Nora Johnson,Retired Vice Chairman, Goldman Sachs, since 2007. During her 21-year tenure with Goldman Sachs, she served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Health Care.Board Chair of Intuit Inc. Co-Chair, Board of Trustees of The Brookings Institution; Member of the Board of Trustees of the Carnegie Institution of Washington and Chair of the Board of Trustees of the University of Southern California. Member of the American Academy of Arts and Sciences. Director of American International Group, Inc. from 2008 to 2020 and Visa, Inc. from 2007 to 2022.
Ronald E. Blaylock

Ronald E. Blaylock先生自2006年担任GenNx360资本合伙人公司创始人以及任事股东,该公司是一家私人实体全面收购下的公司。Blaylock先生是Blaylock股份分公司创始人,主席以及首席执行官,该公司是一家投资银行企业,在2003年Blaylock公司创办前,他同时在韦伯公司集团以及花旗集团担任高级管理职务。Blaylock先生自2007年至今是卡麦斯公司董事,自2001年至今是W. R. Berkley公司董事。Blaylock先生创办并管理的两家金融服务公司为他提供了宝贵的业务、领导和管理经验。因此,Blaylock先生向公司董事会带来了大量金融专业知识。另外,Blaylock先生在其他上市公司董事会的任职经验使他能够向董事会带来另外的观点以及经验。


Ronald E. Blaylock,is the founder and Managing Partner of GenNx360 Capital Partners, a private-equity buyout fund focused on industrial business-to-business companies. Prior to founding GenNx360 in 2006, Mr. Blaylock was Chief Executive Officer of Blaylock & Company, a full-service investment banking firm that he founded in 1993. Previously, Mr. Blaylock held senior management positions with PaineWebber and Citigroup.
Ronald E. Blaylock先生自2006年担任GenNx360资本合伙人公司创始人以及任事股东,该公司是一家私人实体全面收购下的公司。Blaylock先生是Blaylock股份分公司创始人,主席以及首席执行官,该公司是一家投资银行企业,在2003年Blaylock公司创办前,他同时在韦伯公司集团以及花旗集团担任高级管理职务。Blaylock先生自2007年至今是卡麦斯公司董事,自2001年至今是W. R. Berkley公司董事。Blaylock先生创办并管理的两家金融服务公司为他提供了宝贵的业务、领导和管理经验。因此,Blaylock先生向公司董事会带来了大量金融专业知识。另外,Blaylock先生在其他上市公司董事会的任职经验使他能够向董事会带来另外的观点以及经验。
Ronald E. Blaylock,is the founder and Managing Partner of GenNx360 Capital Partners, a private-equity buyout fund focused on industrial business-to-business companies. Prior to founding GenNx360 in 2006, Mr. Blaylock was Chief Executive Officer of Blaylock & Company, a full-service investment banking firm that he founded in 1993. Previously, Mr. Blaylock held senior management positions with PaineWebber and Citigroup.
Helen H. Hobbs

Helen H. Hobbs,霍华德·休斯医学院研究员,自2002年起担任内科和分子遗传学教授,德克萨斯大学西南医学中心麦克德莫特人类生长与发展中心主任。Atavistik Bio董事会成员,专栏组科学顾问。美国临床调查学会和美国医师协会会员。2004年入选美国国家医学院,2006年入选美国艺术与科学院,2007年入选美国科学院。2012年获得首届国际动脉粥样硬化学会奖。2015年获得Pearl Meister Greengard奖,2015年获得生命科学突破奖,2016年获得Passano奖,2018年获得Harrington医学创新奖,2018年度获得Lefoulon Delalande科学大奖,2019年度获得Gerald D.Aurbach杰出转化研究奖,2019年度荣获Anitshkow奖。


Helen H. Hobbs,Investigator, Howard Hughes Medical Institute since 2002, Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Board Member of Atavistik Bio. Scientific Advisor of the Column Group and Colossal Biosciences. Member of the American Society for Clinical Investigation and the Association of American Physicians. Elected to the National Academy of Medicine in 2004, the American Academy of Arts and Sciences in 2006, and the National Academy of Sciences in 2007. In 2012, received the inaugural International Society of Atherosclerosis Prize. Received the Pearl Meister Greengard Award (2015) and the Breakthrough Prize in Life Sciences (2015); the Passano Award (2016); the Harrington Prize for Innovation in Medicine (2018); the Lefoulon-Delalande Grand Prize in Science (2018); the Gerald D. Aurbach Award for Outstanding Translational Research (2019); and the Anitschkow Prize (2019).
Helen H. Hobbs,霍华德·休斯医学院研究员,自2002年起担任内科和分子遗传学教授,德克萨斯大学西南医学中心麦克德莫特人类生长与发展中心主任。Atavistik Bio董事会成员,专栏组科学顾问。美国临床调查学会和美国医师协会会员。2004年入选美国国家医学院,2006年入选美国艺术与科学院,2007年入选美国科学院。2012年获得首届国际动脉粥样硬化学会奖。2015年获得Pearl Meister Greengard奖,2015年获得生命科学突破奖,2016年获得Passano奖,2018年获得Harrington医学创新奖,2018年度获得Lefoulon Delalande科学大奖,2019年度获得Gerald D.Aurbach杰出转化研究奖,2019年度荣获Anitshkow奖。
Helen H. Hobbs,Investigator, Howard Hughes Medical Institute since 2002, Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Board Member of Atavistik Bio. Scientific Advisor of the Column Group and Colossal Biosciences. Member of the American Society for Clinical Investigation and the Association of American Physicians. Elected to the National Academy of Medicine in 2004, the American Academy of Arts and Sciences in 2006, and the National Academy of Sciences in 2007. In 2012, received the inaugural International Society of Atherosclerosis Prize. Received the Pearl Meister Greengard Award (2015) and the Breakthrough Prize in Life Sciences (2015); the Passano Award (2016); the Harrington Prize for Innovation in Medicine (2018); the Lefoulon-Delalande Grand Prize in Science (2018); the Gerald D. Aurbach Award for Outstanding Translational Research (2019); and the Anitschkow Prize (2019).

高管简历

中英对照 |  中文 |  英文
Albert Bourla

Albert Bourla,2014年1月担任一家肿瘤学和消费者保健公司,疫苗的集团总裁。2010年12月到2013年12月担任既定产品业务部门的董事长和总经理。2009年到2010年11月担任Pfizer动物保健欧洲,非洲,亚洲和太平洋地区的总裁。2005年到2009年担任Pfizer动物保健欧洲,非洲和中东地区的总裁。


Albert Bourla,Chairman of the Board since January 2020 and Chief Executive Officer since January 2019. Chief Operating Officer from January 2018 until December 2018. Group President, Pfizer Innovative Health from June 2016 until December 2017. Group President, Global Innovative Pharma Business (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) from February 2016 until June 2016. President and General Manager of Established Products Business Unit from December 2010 until December 2013. Pfizer Inc. Director since February 2018.
Albert Bourla,2014年1月担任一家肿瘤学和消费者保健公司,疫苗的集团总裁。2010年12月到2013年12月担任既定产品业务部门的董事长和总经理。2009年到2010年11月担任Pfizer动物保健欧洲,非洲,亚洲和太平洋地区的总裁。2005年到2009年担任Pfizer动物保健欧洲,非洲和中东地区的总裁。
Albert Bourla,Chairman of the Board since January 2020 and Chief Executive Officer since January 2019. Chief Operating Officer from January 2018 until December 2018. Group President, Pfizer Innovative Health from June 2016 until December 2017. Group President, Global Innovative Pharma Business (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) from February 2016 until June 2016. President and General Manager of Established Products Business Unit from December 2010 until December 2013. Pfizer Inc. Director since February 2018.
Lidia Fonseca

Lidia Fonseca是Pfizer, Inc.的执行副总裁、首席数字和技术官,负责企业范围的数字、数据和技术战略、产品和解决方案,以及学习和发展和业务流程卓越功能,她自2019年1月以来一直担任该职位。2014年4月至2018年12月,Fonseca女士担任Quest Diagnostics的高级副总裁兼首席信息官。此前,从2008年到2013年,她担任Labcorp的高级副总裁兼首席信息官。她被美国拉丁裔专业人士协会评为2020年和2021年50位最具影响力的拉丁裔人,被医学、营销和媒体评为2020年医疗保健影响者和2019年医疗保健变革者,并获得2017年福布斯CIO创新奖。


Lidia Fonseca,Chief Digital and Technology Officer, Executive Vice President since January 2019. Chief Information Officer and Senior Vice President of Quest Diagnostics Incorporated from 2014 to 2018. Senior Vice President of Laboratory Corporation of America Holdings from 2008 until March 2013. Director of Tegna, Inc. from 2014 to 2023. Director of Medtronic plc.
Lidia Fonseca是Pfizer, Inc.的执行副总裁、首席数字和技术官,负责企业范围的数字、数据和技术战略、产品和解决方案,以及学习和发展和业务流程卓越功能,她自2019年1月以来一直担任该职位。2014年4月至2018年12月,Fonseca女士担任Quest Diagnostics的高级副总裁兼首席信息官。此前,从2008年到2013年,她担任Labcorp的高级副总裁兼首席信息官。她被美国拉丁裔专业人士协会评为2020年和2021年50位最具影响力的拉丁裔人,被医学、营销和媒体评为2020年医疗保健影响者和2019年医疗保健变革者,并获得2017年福布斯CIO创新奖。
Lidia Fonseca,Chief Digital and Technology Officer, Executive Vice President since January 2019. Chief Information Officer and Senior Vice President of Quest Diagnostics Incorporated from 2014 to 2018. Senior Vice President of Laboratory Corporation of America Holdings from 2008 until March 2013. Director of Tegna, Inc. from 2014 to 2023. Director of Medtronic plc.
Payal Sahni

Payal Sahni,首席人力资源官,自2020年6月起担任执行副总裁。2016年5月至2020年6月,担任多个运营单位的人力资源高级副总裁。2015年至2016年任人力资源、疫苗、肿瘤和消费者副总裁。自1997年加入辉瑞公司以来,Sahni女士在人力资源组织担任了多个职位,责任越来越重。


Payal Sahni,Chief People Experience Officer, Executive Vice President since January 2022. Chief Human Resources Officer, Executive Vice President from June 2020 to December 2021. From May 2016 until June 2020 served as Senior Vice President of Human Resources for multiple operating units. Vice President of Human Resources, Vaccines, Oncology & Consumer from 2015 until 2016. Ms. Sahni has served in a number of positions in the Human Resources organization with increasing responsibility since joining Pfizer in 1997.
Payal Sahni,首席人力资源官,自2020年6月起担任执行副总裁。2016年5月至2020年6月,担任多个运营单位的人力资源高级副总裁。2015年至2016年任人力资源、疫苗、肿瘤和消费者副总裁。自1997年加入辉瑞公司以来,Sahni女士在人力资源组织担任了多个职位,责任越来越重。
Payal Sahni,Chief People Experience Officer, Executive Vice President since January 2022. Chief Human Resources Officer, Executive Vice President from June 2020 to December 2021. From May 2016 until June 2020 served as Senior Vice President of Human Resources for multiple operating units. Vice President of Human Resources, Vaccines, Oncology & Consumer from 2015 until 2016. Ms. Sahni has served in a number of positions in the Human Resources organization with increasing responsibility since joining Pfizer in 1997.
Aamir Malik

Aamir Malik,首席商业创新官,执行副总裁自2021年8月。麦肯锡公司2019至2021年间在美国的各种领导角色;曾于2015年至2018年共同领导麦肯锡公司的全球药品和医疗产品业务。


Aamir Malik,Chief U.S. Commercial Officer, Executive Vice President since December 2023. Chief Business Innovation Officer, Executive Vice President from August 2021 until December 2023. Various U.S. geographic leadership roles with McKinsey & Company from 2019 to 2021; previously co-led McKinsey & Company's Global Pharmaceuticals & Medical Products practice from 2015 to 2018.
Aamir Malik,首席商业创新官,执行副总裁自2021年8月。麦肯锡公司2019至2021年间在美国的各种领导角色;曾于2015年至2018年共同领导麦肯锡公司的全球药品和医疗产品业务。
Aamir Malik,Chief U.S. Commercial Officer, Executive Vice President since December 2023. Chief Business Innovation Officer, Executive Vice President from August 2021 until December 2023. Various U.S. geographic leadership roles with McKinsey & Company from 2019 to 2021; previously co-led McKinsey & Company's Global Pharmaceuticals & Medical Products practice from 2015 to 2018.
Michael McDermott

Michael McDermott,首席全球供应官,自2022年1月起担任执行副总裁。辉瑞全球供应从2018到2021。2014年至2018年担任辉瑞全球供应副总裁。2012年至2014年担任生物技术部门副总裁。


Michael McDermott,Chief Global Supply Officer, Executive Vice President since January 2022. President of Pfizer Global Supply from 2018 until 2021. Vice President of Pfizer Global Supply from 2014 until 2018. Vice President of the Biotechnology Unit from 2012 until 2014.
Michael McDermott,首席全球供应官,自2022年1月起担任执行副总裁。辉瑞全球供应从2018到2021。2014年至2018年担任辉瑞全球供应副总裁。2012年至2014年担任生物技术部门副总裁。
Michael McDermott,Chief Global Supply Officer, Executive Vice President since January 2022. President of Pfizer Global Supply from 2018 until 2021. Vice President of Pfizer Global Supply from 2014 until 2018. Vice President of the Biotechnology Unit from 2012 until 2014.
Chris Boshoff

Chris Boshoff,首席肿瘤学官,自2023年12月起担任执行副总裁。2023年7月至2023年12月任首席肿瘤学研发官兼执行副总裁。肿瘤学高级副总裁,2017年至2023年。


Chris Boshoff,Chief Oncology Officer, Executive Vice President since December 2023. Chief Oncology Research and Development Officer and Executive Vice President from July 2023 until December 2023. Senior Vice President, Oncology, from 2017 until 2023.
Chris Boshoff,首席肿瘤学官,自2023年12月起担任执行副总裁。2023年7月至2023年12月任首席肿瘤学研发官兼执行副总裁。肿瘤学高级副总裁,2017年至2023年。
Chris Boshoff,Chief Oncology Officer, Executive Vice President since December 2023. Chief Oncology Research and Development Officer and Executive Vice President from July 2023 until December 2023. Senior Vice President, Oncology, from 2017 until 2023.
Alexandre de Germay

Alexandre de Germay,首席国际商务官,自2023年12月起任执行副总裁。Laboratoires Majorelle(一家位于法国、致力于女性健康和泌尿外科的专业制药公司)首席执行官,2021年至2024年1月(2023年12月15日之后协助过渡事宜)。2020年至2021年任高级副总裁;心脏病学、移植和成熟产品全球特许经营负责人,2016年至2020年任赛诺菲成熟市场普药负责人。2013年至2016年任辉瑞公司亚太区域总裁。


Alexandre de Germay,Chief International Commercial Officer, Executive Vice President since December 2023. Chief Executive Officer, Laboratoires Majorelle (a specialty pharma company based in France dedicated to women's health and urology) from 2021 until January 2024 (assisting with transition matters after December 15, 2023). From 2020 until 2021 was Senior Vice President; Global Franchise Head of Cardiology, Transplant and Established Products, and from 2016 until 2020 was Head of Mature Markets General Medicines of Sanofi. Regional President of Asia-Pacific of Pfizer Inc. from 2013 until 2016.
Alexandre de Germay,首席国际商务官,自2023年12月起任执行副总裁。Laboratoires Majorelle(一家位于法国、致力于女性健康和泌尿外科的专业制药公司)首席执行官,2021年至2024年1月(2023年12月15日之后协助过渡事宜)。2020年至2021年任高级副总裁;心脏病学、移植和成熟产品全球特许经营负责人,2016年至2020年任赛诺菲成熟市场普药负责人。2013年至2016年任辉瑞公司亚太区域总裁。
Alexandre de Germay,Chief International Commercial Officer, Executive Vice President since December 2023. Chief Executive Officer, Laboratoires Majorelle (a specialty pharma company based in France dedicated to women's health and urology) from 2021 until January 2024 (assisting with transition matters after December 15, 2023). From 2020 until 2021 was Senior Vice President; Global Franchise Head of Cardiology, Transplant and Established Products, and from 2016 until 2020 was Head of Mature Markets General Medicines of Sanofi. Regional President of Asia-Pacific of Pfizer Inc. from 2013 until 2016.
Jennifer B. Damico
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
David M. Denton

David M. Denton,他自2010年1月起担任CVS Caremark公司执行副总裁兼首席财务官;2008年3月至2009年12月,曾任CVS Caremark Corporation的高级副总裁兼总监/首席会计官;2007年4月至2008年3月,曾任CVS Caremark Corporation高级副总裁,财务管理的CVS Caremark公司和CVS Health Corporation。


David M. Denton,Chief Financial Officer, Executive Vice President since May 2022. Executive Vice President, Chief Financial Officer, Lowe's Companies, Inc., from November 2018 until April 2022; Executive Vice President and Chief Financial Officer, CVS Health Corporation (a diversified health solutions company), from January 2010 until November 2018. Director of Tapestry, Inc. from 2014 to 2023. Director of Haleon plc.
David M. Denton,他自2010年1月起担任CVS Caremark公司执行副总裁兼首席财务官;2008年3月至2009年12月,曾任CVS Caremark Corporation的高级副总裁兼总监/首席会计官;2007年4月至2008年3月,曾任CVS Caremark Corporation高级副总裁,财务管理的CVS Caremark公司和CVS Health Corporation。
David M. Denton,Chief Financial Officer, Executive Vice President since May 2022. Executive Vice President, Chief Financial Officer, Lowe's Companies, Inc., from November 2018 until April 2022; Executive Vice President and Chief Financial Officer, CVS Health Corporation (a diversified health solutions company), from January 2010 until November 2018. Director of Tapestry, Inc. from 2014 to 2023. Director of Haleon plc.
Mikael Dolsten

Mikael Dolsten,2010年12月起担任全球研发部的总裁。2010年5月到2010年12月担任全球研究和发展部的高级副总裁,总裁。2009年10月到2010年5月担任Pfize生物治疗药物研发部高级副总裁,总裁。2008年6月到2009年10月担任惠氏的高级副总裁和惠氏研究部的总裁。2008年1月到2008年6月在OrbiMed顾问有限责任公司担任私人股本合作伙伴。


Mikael Dolsten,Chief Scientific Officer, President, Pfizer Research and Development since July 2023. Chief Scientific Officer and President, Worldwide Research, Development and Medical from January 2019 until July 2023. President of Worldwide Research and Development from December 2010 until December 2018. Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until May 2010. Director of Agilent Technologies, Inc, and Vimian Group AB.
Mikael Dolsten,2010年12月起担任全球研发部的总裁。2010年5月到2010年12月担任全球研究和发展部的高级副总裁,总裁。2009年10月到2010年5月担任Pfize生物治疗药物研发部高级副总裁,总裁。2008年6月到2009年10月担任惠氏的高级副总裁和惠氏研究部的总裁。2008年1月到2008年6月在OrbiMed顾问有限责任公司担任私人股本合作伙伴。
Mikael Dolsten,Chief Scientific Officer, President, Pfizer Research and Development since July 2023. Chief Scientific Officer and President, Worldwide Research, Development and Medical from January 2019 until July 2023. President of Worldwide Research and Development from December 2010 until December 2018. Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until May 2010. Director of Agilent Technologies, Inc, and Vimian Group AB.
Douglas M. Lankler

Douglas M. Lankler,2013年12月担任执行副总裁和法律总顾问。2014年1月到2014年2月担任公司秘书。2011年2月到2013年12月担任执行副总裁,首席合规和风险官。2010年12月到2011年2月担任执行副总裁,首席合规官。2010年1月到2010年12月担任高级副总裁和首席合规官。2009年8月至2010年1月担任高级副总裁,副顾问和首席合规官。2006年10月到2009年8月担任高级副总裁,法律副顾问和首席合规官。


Douglas M. Lankler,General Counsel, Executive Vice President since December 2013. Corporate Secretary from January 2014 until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013.
Douglas M. Lankler,2013年12月担任执行副总裁和法律总顾问。2014年1月到2014年2月担任公司秘书。2011年2月到2013年12月担任执行副总裁,首席合规和风险官。2010年12月到2011年2月担任执行副总裁,首席合规官。2010年1月到2010年12月担任高级副总裁和首席合规官。2009年8月至2010年1月担任高级副总裁,副顾问和首席合规官。2006年10月到2009年8月担任高级副总裁,法律副顾问和首席合规官。
Douglas M. Lankler,General Counsel, Executive Vice President since December 2013. Corporate Secretary from January 2014 until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013.
Sally Susman

Sally Susman自2022年5月起担任Ul Solutions Inc.董事会成员。她目前担任辉瑞制药公司(Pfizer Inc.)(纽约证券交易所代码:PFE)的执行副总裁兼首席企业事务官,该公司是一家跨国制药和生物技术公司。在此之前,她从2010年至2018年担任辉瑞公司的执行副总裁,负责企业事务(前身为政策、外部事务和传播)。在2007年加入辉瑞公司之前,Susman女士曾在雅诗兰黛公司(Estée Lauder Companies Inc.)(纽约证券交易所代码:EL)担任首席传播官,该公司是一家生产和销售护肤品、化妆品、香水和护发产品的制造商和营销公司,任职期间为1999年至2007年。从1990年至1996年,Susman女士曾担任美国运通公司(American Express Company)(纽约证券交易所代码:AXP)的全球传播执行副总裁。Susman女士目前还担任全球人道主义援助、救济和发展非营利组织国际救援委员会(IRC)董事会联席主席。她获得了康涅狄格学院(Connecticut College)政治学学士学位。


Sally Susman,has served as a member of Ul Solutions Inc. board of directors since May 2022. She currently serves as the Executive Vice President and Chief Corporate Affairs Officer for Pfizer Inc. ("Pfizer") (NYSE: PFE), a multinational pharmaceutical and biotechnology company, and, before that, she served as Pfizer's Executive Vice President of Corporate Affairs (formerly Policy, External Affairs and Communications) from 2010 to 2018. Before joining Pfizer in 2007, Ms. Susman served as the Chief Communications Officer of the Estée Lauder Companies Inc. (NYSE: EL), a manufacturer and marketer of skincare, makeup, fragrance and hair care products, from 1999 to 2007. From 1990 to 1996, Ms. Susman served as Executive Vice President of Global Communications for the American Express Company (NYSE: AXP). Ms. Susman is currently the co-chair of the board of directors of the International Rescue Committee, a global humanitarian aid, relief and development nonprofit organization, and is also a member of the Council on Foreign Relations. She earned a B.A. in Government from Connecticut College.
Sally Susman自2022年5月起担任Ul Solutions Inc.董事会成员。她目前担任辉瑞制药公司(Pfizer Inc.)(纽约证券交易所代码:PFE)的执行副总裁兼首席企业事务官,该公司是一家跨国制药和生物技术公司。在此之前,她从2010年至2018年担任辉瑞公司的执行副总裁,负责企业事务(前身为政策、外部事务和传播)。在2007年加入辉瑞公司之前,Susman女士曾在雅诗兰黛公司(Estée Lauder Companies Inc.)(纽约证券交易所代码:EL)担任首席传播官,该公司是一家生产和销售护肤品、化妆品、香水和护发产品的制造商和营销公司,任职期间为1999年至2007年。从1990年至1996年,Susman女士曾担任美国运通公司(American Express Company)(纽约证券交易所代码:AXP)的全球传播执行副总裁。Susman女士目前还担任全球人道主义援助、救济和发展非营利组织国际救援委员会(IRC)董事会联席主席。她获得了康涅狄格学院(Connecticut College)政治学学士学位。
Sally Susman,has served as a member of Ul Solutions Inc. board of directors since May 2022. She currently serves as the Executive Vice President and Chief Corporate Affairs Officer for Pfizer Inc. ("Pfizer") (NYSE: PFE), a multinational pharmaceutical and biotechnology company, and, before that, she served as Pfizer's Executive Vice President of Corporate Affairs (formerly Policy, External Affairs and Communications) from 2010 to 2018. Before joining Pfizer in 2007, Ms. Susman served as the Chief Communications Officer of the Estée Lauder Companies Inc. (NYSE: EL), a manufacturer and marketer of skincare, makeup, fragrance and hair care products, from 1999 to 2007. From 1990 to 1996, Ms. Susman served as Executive Vice President of Global Communications for the American Express Company (NYSE: AXP). Ms. Susman is currently the co-chair of the board of directors of the International Rescue Committee, a global humanitarian aid, relief and development nonprofit organization, and is also a member of the Council on Foreign Relations. She earned a B.A. in Government from Connecticut College.
Rady A. Johnson

Rady A. Johnson,2013年12月起担任执行副总裁,首席合规及风险官。2006年10月到2013年12月担任高级副总裁和副顾问。


Rady A. Johnson,Chief Compliance, Quality and Risk Officer, Executive Vice President since January 2019. Executive Vice President, Chief Compliance and Risk Officer from December 2013 until December 2018. Senior Vice President and Associate General Counsel from October 2006 until December 2013.
Rady A. Johnson,2013年12月起担任执行副总裁,首席合规及风险官。2006年10月到2013年12月担任高级副总裁和副顾问。
Rady A. Johnson,Chief Compliance, Quality and Risk Officer, Executive Vice President since January 2019. Executive Vice President, Chief Compliance and Risk Officer from December 2013 until December 2018. Senior Vice President and Associate General Counsel from October 2006 until December 2013.